Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1
Authors' conclusion
Among late responders to tirzepatide, the vast majority (90%) achieved 5% or more weight reduction at Week 72. This finding suggests that extending treatment well beyond 12 weeks may allow additional patients to achieve clinically meaningful weight reduction.
Study context
- Population
- Tirzepatide-treated SURMOUNT-1 participants who received ≥75% of assigned doses and had weight measurements at Weeks 0, 12, 24 and 72
- Participants
- 1,545 participants
- Comparison
- Late responders vs early responders to tirzepatide at Week 12
- Late respondersn = 278
- Early respondersn = 1,267reference
- Primary endpoint
- Weight reduction by 12-week response category
- Follow-up
- Weeks 24 and 72
Primary result
As reported in the abstract
Late responders achieving ≥5% body weight reduction · Week 72
Late responders
90%
250 of 278
Further findings
- Late responders achieving ≥5% body weight reduction · Week 24 (end of dose titration)
- 70% · 194 of 278
- Time to reach 5% weight reduction, late responders
- 24.8 · mean · ± 12.7 · weeks
Baseline characteristics
- Male, late vs early responders
- 45% vs. 30%
- Body weight, late vs early responders
- 110.2 vs. 103.6 kg
- Body mass index (BMI), late vs early responders
- 39.1 vs. 37.7 kg/m²
- Waist circumference, late vs early responders
- 117.5 vs. 113.4 cm
Dose response · Weeks 24 and 72
- Higher tirzepatide doses associated with higher proportions achieving various weight reduction thresholds
Original publication
Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1. Diabetes Obes Metab. Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →